omada glp 1 program for GLP-1 Medication Access Omada Health: GLP-1-Focused Telehealth Platform

Global burden of type 2 diabetes mellitus from 1990 to 2021, with projections of prevalence to 2044: a systematic analysis across SDI levels for the global burden of disease study 2021

MPM seems to be an efficient short-term approach to treating cervical radiculopathy

Heres what we know about when generics might hit the market for the most in-demand GLP-1 drugs: Ozempic / Wegovy (semaglutide) Patents begin expiring in March 2026, but Novo Nordisk holds secondary patents that could extend exclusivity into 2033

The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production

Research gaps remain regarding optimal concentrations and timing in different tissue types